USA flag logo/image

An Official Website of the United States Government

Oxalate Reduction by Oral Administration of Oxalate Degrading Enzymes

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96072
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
DK089720
Solicitation Year:
N/A
Solicitation Topic Code:
NIDDK
Solicitation Number:
N/A
Small Business Information
CAPTOZYME, LLC
5745 SW 75TH ST, STE 298 GAINESVILLE, FL -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Oxalate Reduction by Oral Administration of Oxalate Degrading Enzymes
Agency: HHS
Contract: 1R43DK089720-01
Award Amount: $150,788.00
 

Abstract:

DESCRIPTION (provided by applicant): Severe diseases or conditions such as primary hyperoxaluria (PH), secondary hyperoxaluria (SH), and Zellweger spectrum disorders (ZSD) continues to be a healthcare problem. These diseases occur when oxalate is readily a bsorbed from dietary sources or from liver overproduction. Oxalate absorption and secretion occur throughout the entire gastrointestinal (GI) tract, but net flow reflects absorption. High concentrations of oxalate and deposition of calcium oxalate (CaOx) c rystals in the kidneys can evoke an inflammatory response and induce tubulointerstitial damage leading to fibrosis, loss of nephrons, and eventually to chronic and end-stage renal failure. CaOx supersaturation in blood can result in CaOx crystal deposition in multiple organs, which can cause organ dysfunction or transplanted organ failure. There is currently no effective treatment for such conditions. Therefore, the approach underlying this application is to reduce urinary and plasma oxalate by limiting die tary absorption and by increasing the oxalate secretion rate from the blood to the GI tract where soluble metabolically derived oxalate can be continuously removed by two highly active purified oxalate-degrading enzymes that are capable of removing oxalate throughout the vast GI tract. PUBLIC HEALTH RELEVANCE: Severe disease conditions, such as primary hyperoxaluria, secondary hyperoxaluria, and Zellweger sprectrum disorders, which are the result of increased dietary absorption or metabolic synthesi s of oxalate continues to be a healthcare problem. Since there is currently no effective treatment at degrading oxalate throughout the entire GI tract, Captozyme is proposing to develop a combination of oxalate-degrading enzymes that can effectively interc ept dietary oxalate as well as remove metabolically generated oxalate throughout the vast GI tract.

Principal Investigator:

Qingshan Li

Business Contact:

Cowley
aaron.cowley@captozyme.com
Small Business Information at Submission:

CAPTOZYME, LLC
CAPTOZYME, LLC 5745 SW 75TH ST, STE 298 GAINESVILLE, FL 32608

EIN/Tax ID: 127032951
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No